{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319523929728.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1365-2036.2010.04474.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2010.04474.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2010.04474.x"}}],"dc:title":[{"@value":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:label /><jats:p> <jats:italic>Aliment Pharmacol Ther</jats:italic> 2010; <jats:bold>32:</jats:bold> 1323–1331</jats:p></jats:sec><jats:sec><jats:title>Summary</jats:title><jats:p><jats:bold>Background </jats:bold> On‐treatment predictors of response to peginterferon can guide individualization of therapy in chronic hepatitis B virus infection.</jats:p><jats:p><jats:bold>Aim </jats:bold> To investigate the use of serum hepatitis B surface antigen quantification to predict sustained response.</jats:p><jats:p><jats:bold>Methods </jats:bold> Hepatitis B e antigen‐positive chronic hepatitis B patients who received peginterferon for 32–48 weeks with or without lamivudine combination were studied. Sustained response was defined as hepatitis B e antigen seroconversion and chronic hepatitis B virus DNA <10 000 copies/mL until 12 months post‐treatment.</jats:p><jats:p><jats:bold>Results </jats:bold> Twenty‐one of 92 (23%) patients achieved sustained response. At month 6, the area under receiver operating characteristics curve for hepatitis B surface antigen to predict sustained response was 0.77 (95% confidence interval 0.65–0.89, <jats:italic>P</jats:italic> < 0.001). An hepatitis B surface antigen cutoff at 300 IU/mL at month 6 could give the maximum combination of sensitivity (62%) and specificity (89%) to predict sustained response. Nine of 21 (43%) sustained responders vs. 9 of 71 (13%) nonsustained responders had >1 log hepatitis B surface antigen reduction at month 6 (<jats:italic>P</jats:italic> < 0.001). Combined hepatitis B surface antigen ≤300 IU/mL and >1 log reduction at month 6 had sensitivity, specificity, positive and negative predictive values of 43%, 96%, 75% and 85% to predict sustained response, respectively.</jats:p><jats:p><jats:bold>Conclusion </jats:bold> On‐treatment serum hepatitis B surface antigen can predict response to peginterferon therapy in chronic hepatitis B.</jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380298345035786884","@type":"Researcher","foaf:name":[{"@value":"H. L.‐Y. Chan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345035786883","@type":"Researcher","foaf:name":[{"@value":"V. W.‐S. Wong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345035786882","@type":"Researcher","foaf:name":[{"@value":"A. M.‐L. Chim"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345035786880","@type":"Researcher","foaf:name":[{"@value":"H.‐Y. Chan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345035786881","@type":"Researcher","foaf:name":[{"@value":"G. L.‐H. Wong"}]},{"@id":"https://cir.nii.ac.jp/crid/1380298345035786885","@type":"Researcher","foaf:name":[{"@value":"J. J.‐Y. Sung"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02692813"},{"@type":"EISSN","@value":"13652036"}],"prism:publicationName":[{"@value":"Alimentary Pharmacology & Therapeutics"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2010-09-29","prism:volume":"32","prism:number":"11-12","prism:startingPage":"1323","prism:endingPage":"1331"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2010.04474.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2010.04474.x"}],"createdAt":"2010-09-29","modifiedAt":"2023-08-31","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235794584192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679772059264","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Comparison of each HBs antigen assay and it's clinical utility"},{"@language":"ja","@value":"HBs抗原の測定法と臨床的意義"},{"@language":"ja-Kana","@value":"HBs コウゲン ノ ソクテイホウ ト リンショウテキ イギ"},{"@value":"Comparison of each HBs antigen assay and it^|^apos;s clinical utility"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282763130206976","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation"},{"@language":"ja","@value":"高感度HBs抗原測定法を用いたB型肝炎再活性化モニタリングの有用性"},{"@language":"ja-Kana","@value":"コウカンド HBs コウゲン ソクテイホウ オ モチイタ Bガタ カンエン サイカッセイカ モニタリング ノ ユウヨウセイ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1365-2036.2010.04474.x"},{"@type":"CROSSREF","@value":"10.1111/jvh.12691_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.310_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"},{"@type":"CROSSREF","@value":"10.2957/kanzo.60.237_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_140XqqXmntBHxi2F068A5Nn6omk"}]}